8613486096626
sales01@huayangco.com
enLanguage
Search

Quinolone Pharmaceutical Intermediates

Home / Products / Quinolone Pharmaceutical Intermediates
Why Choose Us

Certifications

Kaibang takes immense pride in holding certifications from Iso 9001:2015, ISO 14001:2015, andISO 45001:2018, a testament to our unwavering commitment to quality, efficiency, flexibility, and cost competitiveness.

One-Stop Service

We are a professional manufacturer of phar-maceutical intermediates integrating R&D,production and sales.

 

 

Competitive Price

We have a professional purchasing team and costing team, trying to reduce costs and profits, and provide you with a good price.

Production Equipment

We have devoted amount of resource for maintain and keep our equipment in the best state for our customers.

First 12 Last 1/2
Benefits of Quinolone Pharmaceutical Intermediates
 

Broad antibacterial spectrum
Quinolone antibiotics have a broad antibacterial spectrum and can effectively act against Gram-positive bacteria. They also show significant antibacterial effects against most Gram-negative bacteria, such as Pseudomonas aeruginosa.

 

Convenient medication
Quinolone antibiotics are easy to use and can be taken orally, and the adverse reactions they cause are relatively mild, mainly manifesting as gastrointestinal symptoms, central nervous system reactions, and general allergic reactions.

 

Unique antibacterial effect
Quinolone antibiotics have a unique antibacterial action mechanism and can significantly inhibit bacterial DNA and RNA synthesis. Therefore, they have no cross-resistance with other antibacterial drugs and can maintain good antibacterial activity even against strains resistant to other antibacterial drugs.

1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinoline Carboxylic Acid Ethyl Ester C15H12F3NO3 CAS No.: 94242-51-0

 

How Quinolone Pharmaceutical Intermediates antibiotics work

The basic skeleton of quinolone antibiotic molecules is a nitrogen (hetero)biparacyclic structure. Quinolones and other antibacterial drugs have different action points. They target bacterial deoxyribonucleic acid (DNA). The double-stranded DNA of bacteria is twisted into loops or spirals (called supercoils). The enzyme that causes DNA to form supercoils is called DNA gyrase. Quinolones hinder this enzyme, further causing irreversible damage to bacterial DNA and causing bacterial Cells no longer divide. They show selective toxicity to bacteria. Currently, resistance to many antibiotics in some bacteria can be widely spread through plasmid transmission. This class of drugs is not affected by plasmid-transmitted resistance. Therefore, there is no cross-resistance between this class of drugs and many antibacterial drugs.

Quinolones are antibacterial drugs that mainly act on Gram-negative bacteria and have a weak effect on Gram-positive bacteria (some varieties have better antibacterial effects on Staphylococcus aureus).

What Are The Main Functions of Quinolones?

 

Antibacterial

The main antibacterial mechanism of quinolone antibiotics is to kill bacteria by inhibiting bacterial DNA synthesis. It has good antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and some anaerobic bacteria, and can be used clinically to treat respiratory tract infections, skin and soft tissue infections, urinary system infections, and gastrointestinal infections caused by sensitive bacteria. and other diseases.

Anti-inflammatory

Quinolone antibiotics can also inhibit the release of inflammatory mediators, thereby achieving anti-inflammatory effects, and have good therapeutic effects on inflammation caused by various non-bacterial infectious diseases, such as acute rhinitis, acute exacerbation of chronic bronchitis, pneumonia, and acute pyelonephritis. wait.

1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinoline Carboxylic Acid Ethyl Ester CAS No.: 94242-51-0
 
Types of Quinolone Pharmaceutical Intermediates
 
01/

1-Cyclorpropyl-6,7-Difluoro-1,4-Dihydro-4-Oxo-3-Quinoline Carboxylic Acid
1-Cyclorpropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinoline Carboxylic Acid is a chemical compound that belongs to the class of quinolones, which are a group of synthetic antibiotics. This compound is derived from the parent compound quinoline, and it has a unique structure due to the presence of a cyclopropyl group at the first position and a carboxylic acid group at the third position.

02/

1-(6-Amino-3,5-Difluoro-2-Pyridinyl)-6,7-Difluoro-1,4-Dihydro-4-Oxo-3-Quinolinecarboxylic Acid
1-(6-Amino-3,5-difluoro-2-pyridinyl)-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid is a chemical compound widely used in the pharmaceutical industry as an antibacterial agent. This compound is a member of the quinolone family of antibiotics and works by inhibiting the growth and replication of bacteria.

03/

1-(6-Amino-3,5-Difluoro-2-Pyridinyl)-8-Chloro-6,7-Difluoro-1,4-Dihydro-4-Oxo-3-Quinolinecarboxylic Acid
1-(6-Amino-3,5-difluoro-2-pyridinyl)-8-chloro-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid, also known as ADQ-1, is a novel compound with potential therapeutic applications in the treatment of bacterial infections.

04/

1-Cyclorpropyl-6,7-Difluoro-1,4-Dihydro-4-Oxo-3-Quinoline Carboxylic Acid≥99.0%
Cyclorpropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinoline Carboxylic Acid, also known as CFX, is a remarkable compound that has brought about a significant change in our daily lives. This drug has been widely used for its antibacterial properties, and it has been instrumental in fighting against various bacterial infections.

 

4-Methoxymethyl-2,3,5,6-tetrafluorobenzyl Alcohol CAS No.: 83282-91-1

Possible Future Developments of Quinolones

 

Of the fluoroquinolones currently licensed, ciprofloxacin has the broadest spectrum of activity, while ofloxacin is well-distributed into tissues. Both of these compounds are tolerated well by man. A variety of unforeseen effects, including the temafloxacin syndrome, have resulted in the disappearance of many potential‘block-busters. Therefore, it may be time to look for alternative molecules that also attack bacteria via DNA gyrase. Such a group of molecules were ‘showcased’ at the 1994 Interscience Conference on Antimicrobial Agents and Chemotherapy by the Abbott company.

This new group-2-pyridones (Fig. 3)–act on DNA gyrase [18, 19] and, probably, topoisomerase IV (which is a homologue of DNA gyrase). This enzyme appears to play a role in the separation of the daughter DNA molecules after replication. The precise interplay between quinolones and this enzyme is unknown. Of these new 2-pyridones, ABT 719 has considerable antibacterial activity, including gram-positive bacteria and anaerobes. It possesses greater activity than the best current gram-negative quinolone, cipro-floxacin, against both enterobacteria and pseudomonads.

Quinolone Bacterial Resistance

 

The accumulation of several bacterial mutations (DNA gyrase and bacterial permeability) has been associated with the development of very high minimum inhibitory concentrations to ciprofloxacin in isolates of Staphylococcus aureus, Enterobacteriaceae species and P. aeruginosa.

Resistance to quinolones can also develop because of alterations in bacterial permeability and the development of efflux pumps. This resistance mechanism is shared with antimicrobial agents structurally unrelated to the quinolones, such as the betalactams, tetracyclines and chloramphenicol (Chloromycetin).

Cross-resistance among the quinolones is expected, but the extent to which the minimum inhibitory concentration is affected varies from agent to agent. Therefore, the bacterial susceptibility and pharmacokinetic profiles of each quinolone should be considered in determining the effectiveness of specific agents.2

4-Methoxymethyl-2,3,5,6-tetrafluorobenzyl Alcohol
Quinolones Play an Important Role
 

We review data on the in-vitro, ex-vivo, in-vivo, and clinical effects of fluoroquinolones on the synthesis of cytokines and their mechanisms of immunomodulation. In general, most fluoroquinolone derivatives superinduce in-vitro interleukin 2 synthesis but inhibit synthesis of interleukin 1 and tumour necrosis factor (TNF); α furthermore, they enhance significantly the synthesis of colony-stimulating factors (CSF). Fluoroquinolones affect in-vivo cellular and humoral immunity by attenuating cytokine responses. Interleukins 10 and 12 have an important role in the functional differentiation of immunocompetent cells and trigger the initiation of the acquired immune response. In addition, certain fluoroquinolones were seen to enhance haematopoiesis by increasing the concentrations of CSF in the lung as well as in the bone marrow and shaft.

Those fluoroquinolones exerting significant effects on haematopoiesis were those with a cyclopropyl moiety at position N1 of their quinolone core structure. Mechanisms that could explain the various immunomodulatory effects of fluoroquinolones include: (1) an effect on intracellular cyclic adenosine-3,5-monophosphate and phosphodiesterases; (2) an effect on transcription factors such as nuclear factor (NF) κB, activator protein 1, NF-interleukin-6 and nuclear factor of activated T cells; and (3) a triggering effect on the eukaryotic equivalent of bacterial SOS response with its ensuing intracellular events. Further studies are required, especially in the clinical setting to exploit fully the potential of the immunomodulatory effect of fluoroquinolones during, for example, immunosuppression, chronic airway inflammatory diseases, and sinusitis.

Potential Strategies for Quinolones
 

The quinolone antibiotics arose in the early 1960s, with the first examples possessing a narrow-spectrum of activity with unfavorable pharmacokinetic properties. Over time, the development of new quinolone antibiotics has led to improved analogues with an expanded spectrum and high efficacy. Nowadays, quinolones are widely used for treating a variety of infections. Quinolones are broad-spectrum antibiotics that are active against both Gram-positive and Gram-negative bacteria, including mycobacteria, and anaerobes. They exert their actions by inhibiting bacterial nucleic acid synthesis through disrupting the enzymes topoisomerase IV and DNA gyrase, and by causing breakage of bacterial chromosomes.

However, bacteria have acquired resistance to quinolones, similar to other antibacterial agents, due to the overuse of these drugs. Mechanisms contributing to quinolone resistance are mediated by chromosomal mutations and/or plasmid gene uptake that alter the topoisomerase targets, modify the quinolone, and/or reduce drug accumulation by either decreased uptake or increased efflux. This review discusses the development of this class of antibiotics in terms of potency, pharmacokinetics and toxicity, along with the resistance mechanisms which reduce the quinolones' activity against pathogens. Potential strategies for future generations of quinolone antibiotics with enhanced activity against resistant strains are suggested.

≥99.0% Nonafluorobutanesulfonyl Fluoride CAS NO.375-72-4
Our Factory
 

Shaoxing Kaibang New Material Technology Co., Ltd is a company integrating R & D, production, sales,professional Pharmaceutical Intermediates manufacturer, we specialize in the development and production of Active Pharmaceutical Intermediates (APIs) and Pharmaceutical Intermediates, and earned a reputations leading supplier of innovative, high quality chemicals. Shaoxing Kaibang New Material Technology Co., Ltd has a well-established research & kilo laboratory to serve our global customers in multi grams to kilograms level, and also conduct process development, has own production line, Pentafluorophenol, Difluorophenol, Tetrafluorobenzyl Alcohol etc as our main competitive products, highly purified,high quality, well appreciated by their purchasers. 

20231229171640b89f8b0a28a94006b71e5b46a293ba9e
202312291713340b8802745bbc4ef4a3db8fb994cfe693
20231229171338efd6d0dc902a4da4a423f02d6aa307c3
20231229171405c89ab742251b421bb9c6b4f5e8b3caab

 

certificate
 

 

202312251121055684bb8586c74292a6a21b4c274b67b2
20231225112100405c30f31a854472b88fa8ecef898f91
20231225112055358d9cbbcdba4539ba5704130cb924e2
2023122511205199d666261544484596e946e2d2100e6d

 

 
FAQ

Q: What are the drugs of choice for fluoroquinolones?

A: Fluoroquinolones are a class of antibiotics approved to treat or prevent certain bacterial infections. The fluoroquinolone antibiotics include ciprofloxacin (Cipro), gemifloxacin (Factive), levofloxacin (Levaquin), moxifloxacin (Avelox), and ofloxacin (Floxin).

Q: What is the most potent quinolones?

A: Ciprofloxacin remains the most potent marketed fluoroquinolone against gram-negative bacteria, and it and levofloxacin in the United States and sitafloxacin in Japan are the only available quinolones with sufficient potency for use against susceptible strains of P. aeruginosa.

Q: What is the safest quinolone to use?

A: Ciprofloxacin remains the safest quinolone to date, as confirmed through in vitro and in vivo models and from postmarketing experience.Nowadays, quinolones are widely used for treating a variety of infections. Quinolones are broad-spectrum antibiotics that are active against both Gram-positive and Gram-negative bacteria, including mycobacteria, and anaerobes.

Q: What is the specific target of quinolones?

A: The quinolones are a potent group of drugs that target the essential bacterial enzymes DNA gyrase and topoisomerase IV. DNA gyrase is the primary target of Gram negative organisms however, it is topoisomerase IV that is the primary target of Gram positive organisms.

Q: Which is the best fluoroquinolone?

A: A guideline by the National Institute for Health and Care Excellence (NICE) recommends ciprofloxacin for pyelonephritis for non-pregnant women and men aged 16 years and over. In the other three guidelines, both ciprofloxacin and levofloxacin are recommended for acute pyelonephritis.

Q: Is levofloxacin more potent than ciprofloxacin?

A: Some studies (5) showed that levofloxacin had better antibacterial effect against Gram-positive bacteria than ciprofloxacin. But others (6) have shown that the efficacy of the two is equivalent.Moxifloxacin ranked with the highest probability for cardiovascular adverse events. Further study is required to determine how to reduce the risk for fluoroquinolone-associated cardiac toxicity.

Q: What is the difference between a quinolone and a fluoroquinolone?

A: Some people use the words quinolones and fluoroquinolones interchangeably, but fluoroquinolones are the only class of quinolones still available. For this reason, the term fluoroquinolones will be used from now on.Ciprofloxacin has better activity against gram-negative bacilli, an advantage which may be negated by ofloxacin's longer half-life and higher serum levels.

Q: Is Cipro better than levofloxacin for Pseudomonas?

A: Levofloxacin showed better bactericidal activity than ciprofloxacin and ofloxacin in vitro tests seen from the time-kill curve. Ciprofloxacin has bactericidal activity not as good as levofloxacin and almost the same as ofloxacin in vitro tests seen from the time-kill curve.

Q: Which fluoroquinolones have the least bioavailability?

A: Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%. With the exception of norfloxacin the quinolones can be taken orally or administered by the parenteral route.

Q: Who should avoid quinolones?

A: Particular caution should be taken when prescribing fluoroquinolones in older patients, those with renal impairment, solid organ transplantation or on systemic corticosteroids as the risk of some adverse reactions (e.g. tendonitis, tendon rupture) are higher in these patients.Contraindications. Quinolones are not recommended in people with epilepsy, Marfan's syndrome, Ehlers-Danlos Syndrome, QT prolongation, pre-existing CNS lesions, or CNS inflammation, or who have had a stroke. They are best avoided in the athlete population.

Q: When should quinolones be avoided?

A: Quinolones should be avoided in pregnancy and while breastfeeding. All quinolones should be avoided in pregnancy as they have been shown to cause arthropathy in animal studies. There are limited data available on the safety of quinolone use while breastfeeding.

Q: What is the main advantage of levofloxacin over other quinolones?

A: Levofloxacin is well tolerated, and is associated with few of the phototoxic, cardiac or hepatic adverse events seen with some other quinolones. It also has a pharmacokinetic profile that is compatible with once-daily administration and allows for sequential intravenous to oral therapy.

Q: Why are quinolones bad?

A: Fluoroquinolone medicines (which contain ciprofloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin and rufloxacin) can cause long-lasting, disabling and potentially permanent side effects involving tendons, muscles, joints and the nervous system.

Q: What was the first fluoroquinolone?

A: Norfloxacin was the first of the “fluoroquinolones,” a name resulting from the addition of a fluorine at the C-6 position. Other second-generation quinolones include ciprofloxacin, ofloxacin, levofloxacin, enoxacin, fleroxacin, lomefloxacin, pefloxacin, and rufloxacin [4].

Q: Does ciprofloxacin have good oral bioavailability?

A: It is well absorbed, with a bioavailability of 70% to 80%, and penetrates efficiently into most tissue compartments, including the peritoneum.sually 100% bioavailability is assured only for IV medications and not for other routes like intramuscular or subcutaneous route. When a medication is administered intravenously it can directly reach the blood circulation and thereby assure 100% bioavailability.

Q: Why is ciprofloxacin not recommended?

A: Taking ciprofloxacin increases the risk that you will develop tendinitis (swelling of a fibrous tissue that connects a bone to a muscle) or have a tendon rupture (tearing of a fibrous tissue that connects a bone to a muscle) during your treatment or for up to several months afterward.

Q: Can I take levofloxacin instead of ciprofloxacin?

A: Levofloxacin and ciprofloxacin are both recommended for clinical application in UTIs and, though commonly prescribed, there's no final conclusion on the comparative merit of the either one. Levofloxacin shows advantage over ciprofloxacin in terms of efficacy, disease reoccurrence and adverse event (Zhang et al., 2012).

Q: Why should fluoroquinolones be avoided?

A: Potential risks associated with fluoroquinolone use include hypoglycemic coma and certain adverse mental health effects 3; disabling and potentially permanent adverse effects to the tendons, muscles, joints, nerves, and central nervous system 4; peripheral neuropathy 4; and tendinitis and tendon rupture 4.

Q: What is the difference between levofloxacin and ciprofloxacin?

A: Levofloxacin and ciprofloxacin are quinolone antibiotics. Levofloxacin is usually taken once daily, while ciprofloxacin is typically taken twice daily. They can treat a variety of infections, including skin infections, UTIs, and exacerbations of chronic bronchitis.They exhibit excellent oral bioavailability, extensive tissue penetration, low protein binding, and a long elimination half-life.

Q: Which fluoroquinolone has maximum bioavailability?

A: The pharmacokinetic characteristics of levofloxacin, moxifloxacin, and gatifloxacin include excellent oral bioavailability (90–99%), extensive penetration into tissues and body fluids, and an elimination half-life (6–12 hrs) that allows for once-daily dosing in patients with normal renal function.

We're professional quinolone pharmaceutical intermediates manufacturers and suppliers in China, specialized in providing high quality customized service. We warmly welcome you to buy quinolone pharmaceutical intermediates at low price from our factory. Contact us for quotation.

99 0 2 4 Difluorobenzonitrile, 98 0 Dimethyl Fluoromalonate, 1 Cyclorpropyl 6 7 difluoro 1 4 dihydro 4 oxo 3 quinoline Carboxylic Acid 99 0 93107 30 3